FutureChem Co

FutureChem Co Intangible Assets

The Intangible Assets of FutureChem Co (220100.KQ) as of Oct 20, 2026 is 5.67 B KRW. In the previous year, Intangible Assets was 3.98 B KRW — a change of 42.37% (higher).

Intangible Assets

5.67 BKRW

YoY

42.37%

Last updated:

Intangible Assets of FutureChem Co is 2024 5.67 B KRW. Intangible Assets of FutureChem Co was 2023 3.98 B KRW. It decreases by 42.37% higher compared to the previous year.

The FutureChem Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
6.64 B KRW
Jan 1, 2018
837.00 M KRW
Jan 1, 2019
751.00 M KRW
Jan 1, 2020
506.00 M KRW
Jan 1, 2021
2.17 B KRW
Jan 1, 2022
3.03 B KRW
Jan 1, 2023
3.98 B KRW
Jan 1, 2024
5.67 B KRW
The FutureChem Co Intangible Assets history
YEARIntangible AssetsYoY
5.67 BKRW+42.37%
3.98 BKRW+31.26%
3.03 BKRW+40.00%
2.17 BKRW+328.21%
506.00 MKRW-32.62%
751.00 MKRW-10.27%
837.00 MKRW-87.40%
6.64 BKRW+485.89%
1.13 BKRW+16.31%
975.00 MKRW+19.05%
819.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

FutureChem Co Stock analysis

What does FutureChem Co do? FutureChem Co., Ltd. generates revenue through the manufacture and distribution of radiopharmaceuticals, including diagnostic agents for lung cancer, Parkinson's disease, and Alzheimer's disease. The company produces medical automation modules such as cubes, disposable cassettes, reagent kits, radio-caps, and kryptofix kits, alongside PET and SPECT precursors for radiopharmaceuticals. These products are sold to healthcare providers, diagnostic centers, and medical facilities requiring specialized radiopharmaceutical solutions. The firm also develops metal chelating agents and fluorescence probes for medical applications. The primary buyers of FutureChem's products include hospitals, clinics, and research institutions focused on cancer diagnostics and neurological conditions. Medical automation modules and disposable goods are utilized in diagnostic procedures, while PET and SPECT precursors support imaging technologies. Metal chelating agents and fluorescence probes are integrated into medical testing and imaging processes. FutureChem's revenue streams are driven by the demand for advanced diagnostic tools in oncology and neurology. The company's portfolio targets healthcare segments requiring early detection of diseases, with products designed for both diagnostic imaging and laboratory testing. Sales are concentrated in medical facilities that prioritize precision diagnostics and specialized treatment planning. FutureChem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about FutureChem Co stock

Intangible Assets of FutureChem Co is 5.67 B KRW in 2024.

Intangible Assets of FutureChem Co changed from 3.98 B KRW to 5.67 B KRW, representing a 42.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets FutureChem Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's FutureChem Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — FutureChem Co

All Key Metrics — FutureChem Co